{"organizations": [], "uuid": "c02e06f52b28ceb8141588aece321aa1c0113114", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/7", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/03/08/business-wire-catabasis-pharmaceuticals-to-report-fourth-quarter-and-full-year-2017-financial-results-and-recent-corporate-developments-on.html", "country": "US", "domain_rank": 767, "title": "Catabasis Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Financial Results and Recent Corporate Developments on Thursday, March 15", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-08T16:00:00.000+02:00", "replies_count": 0, "uuid": "c02e06f52b28ceb8141588aece321aa1c0113114"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/03/08/business-wire-catabasis-pharmaceuticals-to-report-fourth-quarter-and-full-year-2017-financial-results-and-recent-corporate-developments-on.html", "ord_in_thread": 0, "title": "Catabasis Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Financial Results and Recent Corporate Developments on Thursday, March 15", "locations": [], "entities": {"persons": [{"name": "jill c. milne", "sentiment": "none"}], "locations": [{"name": "mass.", "sentiment": "none"}, {"name": "cambridge", "sentiment": "none"}], "organizations": [{"name": "catabasis pharmaceuticals", "sentiment": "neutral"}]}, "highlightText": "", "language": "english", "persons": [], "text": "The Company will Host a Conference Call at 4:30pm ET\nCAMBRIDGE, Mass.--(BUSINESS WIRE)-- Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, will report fourth quarter and full year 2017 financial results after the NASDAQ Global Market close on Thursday, March 15, 2018. Jill C. Milne, Ph.D., Chief Executive Officer, will host a conference call and webcast at 4:30pm ET to provide an update on corporate developments and to discuss fourth quarter and last year’s financial results.\nConference Call Dial-In Information:\nParticipant Toll-Free Dial-In Number: (877) 388-2733 Participant International Dial-In Number: (541) 797-2984 Pass Code: 7693708 Please specify to the operator that you would like to join the “Catabasis Fourth Quarter and Full Year 2017 Results Call.”\nInterested parties may access a live audio webcast of the conference call via the investor section of the Catabasis website, www.catabasis.com . Please connect to the Catabasis website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary. The webcast will be archived for 90 days.\nAbout Catabasis\nAt Catabasis Pharmaceuticals, our mission is to bring hope and life-changing therapies to patients and their families. Our SMART (Safely Metabolized And Rationally Targeted) Linker drug discovery platform enables us to engineer molecules that simultaneously modulate multiple targets in a disease. We are applying our SMART Linker SM platform to build an internal pipeline of product candidates for rare diseases and plan to pursue partnerships to develop additional product candidates. For more information on the Company's drug discovery platform and pipeline of drug candidates, please visit www.catabasis.com .\nView source version on businesswire.com : http://www.businesswire.com/news/home/20180308005176/en/\nInvestor and Media Contact\nCatabasis Pharmaceuticals, Inc.\nAndrea Matthews, 617-349-1971\namatthews@catabasis.com\nSource: Catabasis Pharmaceuticals, Inc.", "external_links": ["http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.catabasis.com&esheet=51770106&newsitemid=20180308005176&lan=en-US&anchor=www.catabasis.com&index=3&md5=8806a85d1459dd2874c1e561c924797b", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.catabasis.com&esheet=51770106&newsitemid=20180308005176&lan=en-US&anchor=Catabasis+Pharmaceuticals%2C+Inc.&index=1&md5=fff833dd44c4f324a129bf92f45a3811", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.catabasis.com&esheet=51770106&newsitemid=20180308005176&lan=en-US&anchor=www.catabasis.com&index=2&md5=1804f027fd736010faa9aec825722158", "http://www.businesswire.com/news/home/20180308005176/en/"], "published": "2018-03-08T16:00:00.000+02:00", "crawled": "2018-03-08T19:35:50.098+02:00", "highlightTitle": ""}